




Company Overview



NanoBioMagnetics, Inc (NBMI), an Oklahoma Corporation, has as its central business objective the discovery and development of medical therapeutic systems and techniques utilizing nanoparticles. The company's primary focus is on **nanotools** for cancer prevention, diagnosis and treatment. Since 2002, NBMI has brought its expertise in the preparation and configuration of nanoparticles together with medical researchers for multidisciplinary collaborative efforts that have led to several scientific firsts.

Based on a proprietary electromagnetic methodology, in which magnetically responsive nanoparticles (**MNP**), under the influence of an external magnetic field, cause or drive a desired physiological action or event, the company is pursuing a range of healthcare applications within two proprietary technology platforms: (1) **Vectored Drug Delivery** and (2) **Biostable Implants**.

Referred to as Organ-Assisting-Device (**OAD**) technologies, applications under study include:

- ✧ The **Site-Specific Delivery of Chemotherapeutics**: In collaboration with researchers at the MD Anderson Cancer Center, Houston, TX, research results, published at international conferences, demonstrate that magnetically responsive nanoparticles (MNP) can be vectored to a tumor site with tumor penetration under the influence of an external magnetic field.
- ✧ The **Delivery of Bioactive Materials** to the inner ear: In a CRADA with the Office of Naval Research, the use of an external magnetic force successfully demonstrated that MNP could be drawn, atraumatically, through the Round Window Membrane into the inner ear, setting the stage for a delivery mechanism for remediation of sensorineural hearing loss, where none currently exists.
- ✧ **Middle Ear Hearing Amplification**: The potential for middle ear vibration in the amplification of sound was successfully demonstrated in collaboration with the Massachusetts Eye and Ear Infirmary, Harvard Medical School, using MNP modified membranes responding to an oscillating magnetic field.
- ✧ The company is now developing other collaborations that will focus on the site-specific delivery of **genetic materials, stem cells and the development of early stage diagnostics for cancer**.

The business model calls for the development and validation of OAD healthcare applications within NBMI, the repository for all developed Intellectual Property, followed by the spin-off of separate business units for production and commercialization. Through its collaborations, NBMI has effectively demonstrated that **OAD technologies** have the potential to be effective tools in advancing new disruptive product technologies for treating human health diseases.

NBMI intends to participate and lead the creation of this emerging market for medical therapeutic nanoparticles. NBMI's first spin-off, **XetaComp**, now in progress, will generate a revenue stream from the production and commercialization of **sunVex™** sunscreens, broad-spectrum UVA/UVB attenuators, marketed as cancer prevention tools. NBMI's goal is to realize the value of the research work accomplished in the development of novel process technology. The Company is seeking \$1.5MM in investment capital to assist in the launch of the **XetaComp business opportunity**.

NBMI, to continue support of R&D and business operations, and transition from a science organization to a functioning business unit, is seeking investment capital of \$5.0MM over the next five years. The value for investors in NBMI will primarily be realized in its IP holdings, and licensing and royalty revenues from spin-offs. However, at various time points in the future, investors can also look to private/public offerings of stock from established spin-offs, such as XetaComp in ~3 years, as potential exit strategies.

Thus, NBMI offers the investor a significant opportunity to participate in a broad-based emerging technology.